No Data
No Data
Hengrui Pharmaceuticals, Subsidiary Get Regulatory Nod to Test Two Drugs
Jiangsu Hengrui Pharmaceuticals (SHA:600276) and its subsidiary, Shandong Shengdi Pharmaceutical, will conduct clinical trials on two drugs after receiving approval from China's National Medical Produ
Jiangsu Hengrui Pharmaceuticals (600276.SH): HRS7415 tablets, HRS-8080 tablets have obtained the notice of drug clinical trial approval.
On June 17th, Gelunhui reported that Jiangsu Hengrui Pharmaceuticals (600276.SH) and its subsidiary, Shandong Shengdi Pharmaceutical Co., Ltd., received the National Medical Products Administration's approval for clinical trials of HRS7415 tablets and HRS-8080 tablets in the form of a Drug Clinical Trial Approval Notice. HRS7415 tablets inhibit AKT-induced substrate protein phosphorylation, regulate downstream signaling pathways, and thus inhibit cell proliferation, exerting anti-tumor effects. HRS-8080 tablets are a novel, efficient, and selective oral estrogen receptor (ER) degrader, with strong and high selectivity.
Shareholders in Jiangsu Hengrui Medicine (SHSE:600276) Are in the Red If They Invested Three Years Ago
For many investors, the main point of stock picking is to generate higher returns than the overall market. But its virtually certain that sometimes you will buy stocks that fall short of the market a
Hengrui's FORM 483 is not that simple | Jianzhi Research
According to the FDA website, Hengrui's January on-site inspection has entered the OAI phase, which means that the FDA is not satisfied with the company's first-stage response and corrective actions, and has made a formal regulatory decision. However, it should be emphasized that Hengrui still has the opportunity to submit rectification measures before further regulatory measures are taken. And this on-site inspection has nothing to do with the dual AI therapy going global.
Hengrui Pharma Units Get China Nod for Clinical Trial of Tumor Drug
China's medical products administrator approved clinical trials for Jiangsu Hengrui Pharmaceuticals' (SHA:600276) SHR-4849 injection for malignant solid tumors, according to a Wednesday filing with th
Jiangsu Hengrui Pharmaceuticals (600276.SH): Subsidiary's drug to be included in list of breakthrough therapies.
On June 5th, Gelunhui announced that Jiangsu Hengrui Pharmaceuticals (600276.SH) announced that the injection SHR-A1811 of its subsidiary Suzhou Shengdiya Biomedical Pharmaceutical Co., Ltd. was included in the public list of breakthrough therapy varieties proposed by the Drug Evaluation Center of the National Medical Products Administration for a public notice period of 7 days. In addition, the injection SHR-A1811 of the company has obtained breakthrough therapy recognition for five indications. The injection SHR-A1811 can bind and internalize with HER2-expressing tumor cells, release toxins by protease cleavage in tumor cell lysosomes, induce cell cycle arrest, and induce tumor cell apoptosis.
No Data